Initiating therapeutic continuous glucose monitoring (CGM) can affect A1C levels and patients’ relationship to their diabetes. We used real-world A1C data to quantify short-term glycemic changes in people with T2D new to CGM. Eligibility was assessed during calls to Dexcom regarding its G6 CGM system. Criteria included ages 25-65 years, use of intensive insulin therapy (IIT), no prior CGM use, coverage with a non-government health plan, willingness to provide validated A1C values and survey responses at baseline and at ∼12 weeks after CGM initiation, and willingness to share CGM data via CLARITY (Dexcom). Patient-reported outcome (PRO) surveys included the diabetes distress scale (DDS), hypoglycemic attitudes and behavior scale (HABS), and diabetes quality of life short inventory (DQOL). G6 satisfaction and ease of use were also assessed. Data from 39 participants were available for this interim analysis. Compared to baseline, the ∼12-week data showed a mean 1.5 percentage point reduction in A1C (Figure). Nineteen (49%) of the participants had at least a 1 percentage point A1C reduction. PRO scores improved by 31% for the DDS, by 22% for the HABS, and by 24% for the DQOL. Most participants found the G6 system satisfactory or very satisfactory (95%) and very easy to use (85%). Patients with T2D using IIT may experience significant glycemic and psychosocial benefits within 12 weeks of starting G6 CGM.
A. Noar: Employee; Self; Dexcom, Inc., Tandem Diabetes Care. J. Welsh: Employee; Self; CSL Behring. D.A. Price: Employee; Self; Dexcom, Inc.
